APOE and cholesterol homeostasis in Alzheimer's disease

Trends in Molecular Medicine

Volumn 16, Issue 10, 2010, Pages 469-477

  Leduc, Valérie ^a   Jasmin Bélanger, Stéphanie ^a   Poirier, Judes ^a,b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CARRIER PROTEIN; CHOLESTEROL; PROTEIN APOC1; PROTEIN APOJ; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DEMENTIA; DETERIORATION; DIABETES MELLITUS; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; STROKE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CHOLESTEROL; HOMEOSTASIS; HUMANS;

EID: 77957372866     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.07.008     Document Type: Review

References (100)

1. Terry R.D. Alzheimer's disease and the aging brain. J. Geriatr. Psychiatry Neurol. 2006, 19:125-128.
2. Adlard P.A., Cummings B.J. Alzheimer's disease - a sum greater than its parts?. Neurobiol. Aging 2004, 25:725-733.
3. Mattson M.P., Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 2006, 7:278-294.
4. Braak H., et al. Vulnerability of select neuronal types to Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 924:53-61.
5. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997, 20:154-159.
6. Poirier J., et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
7. Corder E.H., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
8. Carrasquillo M.M., et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat. Genet. 2009, 41:192-198.
9. Reiman E.M., et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007, 54:713-720.
10. Li H., et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 2008, 65:45-53.
11. Harold D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
12. Lambert J.C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
13. Boyles J.K., et al. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J. Biol. Chem. 1990, 265:17805-17815.
14. Poirier J., et al. Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat. Brain Res. Mol. Brain Res. 1991, 9:191-195.
15. May P.C., et al. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5:831-839.
16. Poirier J., et al. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 1991, 11:97-106.
17. Kalaria R.N., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008, 7:812-826.
18. Skoog I., Gustafson D. Update on hypertension and Alzheimer's disease. Neurol. Res. 2006, 28:605-611.
19. Thambisetty M., et al. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 2010, 67:93-98.
20. de Leon M.J., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10966-10971.
21. Bondi M.W., et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005, 64:501-508.
22. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
23. Forette F., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
24. Hoffman L.B., et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009, 72:1720-1726.
25. Peila R., et al. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke 2001, 32:2882-2889.
26. Shah K., et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother. 2009, 7:250-261.
27. Mulnard R.A., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a 1-year randomized controlled trial. JAMA 2000, 283:1007-1015.
28. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
29. Hirsch-Reinshagen V., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 2005, 280:43243-43256.
30. Blain J.F., et al. A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neurobiol. Dis. 2004, 15:510-519.
31. Lutjohann D., et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9799-9804.
32. Leoni V. Oxysterols as markers of neurological disease - a review. Scand. J. Clin. Lab Invest. 2009, 69:22-25.
33. Mulder M., et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 1998, 12:198-203.
34. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 1994, 62:1039-1047.
35. Chochina S.V., et al. Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J. Lipid Res. 2001, 42:1292-1297.
36. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement. 2008, 4:S91-97.
37. Beffert U., et al. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res. Brain Res. Rev. 1998, 27:119-142.
38. Poirier J., et al. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993, 55:81-90.
39. Nathan B.P., et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850-852.
40. Beffert U., et al. Functions of lipoprotein receptors in neurons. J. Lipid Res. 2004, 45:403-409.
41. Posse De Chaves E.I., et al. Uptake of lipoproteins for axonal growth of sympathetic neurons. J. Biol. Chem. 2000, 275:19883-19890.
42. Champagne D., et al. Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task. Neuroscience 2002, 114:641-654.
43. Mulder M., et al. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol. Dis. 2004, 16:212-219.
44. Papassotiropoulos A., et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 2002, 36:27-32.
45. Igbavboa U., et al. A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J. Neurochem. 2002, 80:255-261.
46. Klunk W.E., et al. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol. Aging 1998, 19:511-515.
47. Mason R.P., et al. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 1992, 13:413-419.
48. Mauch D.H., et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
49. Dietschy J.M., Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45:1375-1397.
50. Utermann G., et al. Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin. Genet. 1979, 15:63-72.
51. Arendt T., et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 1997, 17:516-529.
52. Sparks D.L., et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
53. Refolo L.M., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
54. Ghribi O., et al. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006, 99:438-449.
55. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003, 9:94-101.
56. Champagne D., et al. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 2003, 121:99-110.
57. Fassbender K., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5856-5861.
58. Refolo L.M., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2001, 8:890-899.
59. Bodovitz S., Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 1996, 271:4436-4440.
60. Giubilei F., et al. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol. Scand. 1990, 81:84-86.
61. Moroney J.T., et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999, 282:254-260.
62. Dehouck B., et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 1997, 138:877-889.
63. Waelsch H., et al. A study of the synthesis and deposition of lipids in brain and other tissues with deuterium as an indicator. J. Biol. Chem. 1940, 135:291-296.
64. Chobanian A.V., Hollander W. Body cholesterol metabolism in man. I. The equilibration of serum and tissue cholesterol. J. Clin. Invest. 1962, 41:1732-1737.
65. Roheim P.S., et al. Apolipoproteins in human cerebrospinal fluid. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:4646-4649.
66. Salen G., et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N. Engl. J. Med. 1987, 316:1233-1238.
67. Igbavboa U., et al. Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochem. 1997, 69:1661-1667.
68. Gibson Wood W., et al. Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta 2003, 1610:281-290.
69. Riddell D.R., et al. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 2001, 11:1288-1293.
70. Kojro E., et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5815-5820.
71. Xiu J., et al. Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem. Int. 2006, 49:459-465.
72. Abad-Rodriguez J., et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 2004, 167:953-960.
73. Puglielli L., et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 2001, 3:905-912.
74. Pani A., et al. Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer's disease. J. Alzheimers Dis. 2009, 18:829-841.
75. Beffert U., et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999, 843:87-94.
76. Riddell D.R., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 2008, 28:11445-11453.
77. Bales K.R., et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 2009, 29:6771-6779.
78. Rebeck G.W., et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580.
79. Holtzman D.M., et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 1999, 103:R15-21.
80. Beffert U., et al. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mol. Brain Res. 1999, 68:181-185.
81. Yang D.S., et al. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 1999, 90:1217-1226.
82. Deane R., et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118:4002-4013.
83. Evans K.C., et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:763-767.
84. Holtzman D.M., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2892-2897.
85. Morris J.A., et al. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem. Biophys. Res. Commun. 1999, 261:493-498.
86. Ohm T.G., et al. Cholesterol and tau protein - findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 2003, 36(Suppl. 2):S120-126.
87. Distl R., et al. Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. 2001, 101:547-554.
88. Chauhan N.B. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J. Ethnopharmacol. 2006, 108:385-394.
89. Jick H., et al. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
90. Wolozin B., et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.
91. Haag M.D., et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2009, 80:13-17.
92. Li G., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007, 69:878-885.
93. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
94. Enjalbert M., et al. Usefulness of probucol in treating primary hypercholesterolemia. Can. Med. Assoc. J. 1980, 123:754-757.
95. Liang Y., et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 2004, 88:623-634.
96. Riddell D.R., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
97. Feldman H.H., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964.
98. Arvanitakis Z., Knopman D.S. Clinical trial efforts in Alzheimer disease. Why test statins?. Neurology 2010, 74:945-946.
99. Poirier J. Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's disease: from risk factors to therapeutic targets. Alzheimer's Disease and Related Disorders Annual 2002, 1-23. Dunitz. S. Gauthier, J.L. Cummings (Eds.).
100. Thompson P.M., et al. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 2003, 23:994-1005.